RU2013133846A - Антитела против il-18 и их применение - Google Patents
Антитела против il-18 и их применение Download PDFInfo
- Publication number
- RU2013133846A RU2013133846A RU2013133846/10A RU2013133846A RU2013133846A RU 2013133846 A RU2013133846 A RU 2013133846A RU 2013133846/10 A RU2013133846/10 A RU 2013133846/10A RU 2013133846 A RU2013133846 A RU 2013133846A RU 2013133846 A RU2013133846 A RU 2013133846A
- Authority
- RU
- Russia
- Prior art keywords
- amino acid
- antibody molecule
- seq
- acid sequence
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Food Science & Technology (AREA)
- Rheumatology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061424920P | 2010-12-20 | 2010-12-20 | |
| US61/424,920 | 2010-12-20 | ||
| PCT/EP2011/073496 WO2012085015A1 (en) | 2010-12-20 | 2011-12-20 | Anti-il-18 antibodies and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013133846A true RU2013133846A (ru) | 2015-01-27 |
Family
ID=45372272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013133846/10A RU2013133846A (ru) | 2010-12-20 | 2011-12-20 | Антитела против il-18 и их применение |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9255144B2 (2) |
| EP (1) | EP2655416A1 (2) |
| JP (1) | JP2014508511A (2) |
| KR (1) | KR20140003467A (2) |
| CN (1) | CN103339147A (2) |
| AU (2) | AU2011347354A1 (2) |
| BR (1) | BR112013015508B1 (2) |
| CA (1) | CA2822515C (2) |
| MX (1) | MX2013007067A (2) |
| RU (1) | RU2013133846A (2) |
| WO (1) | WO2012085015A1 (2) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9376489B2 (en) * | 2012-09-07 | 2016-06-28 | Novartis Ag | IL-18 binding molecules |
| ES2742413T3 (es) * | 2012-11-21 | 2020-02-14 | Km Biologics Co Ltd | Nuevo anticuerpo humano contra IL-18 |
| CN115925928A (zh) * | 2013-09-05 | 2023-04-07 | Ab2生物股份有限公司 | 炎性疾病中的il-18结合蛋白(il-18bp) |
| WO2015160795A1 (en) * | 2014-04-14 | 2015-10-22 | The Regents Of The University Of California | Compositions and methods for treating inflammation |
| US10882905B2 (en) * | 2015-03-05 | 2021-01-05 | Ab2 Bio Sa | IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases |
| FI3592384T3 (fi) | 2017-03-09 | 2025-09-29 | Mab Discovery Gmbh | Vasta-aineita, jotka spesifisesti sitoutuvat ihmisen IL-1R7:ään |
| WO2019213686A1 (en) * | 2018-05-10 | 2019-11-14 | The Council Of The Queensland Institute Of Medical Research | Therapeutic compositions and uses therefor |
| US12269874B2 (en) | 2018-12-03 | 2025-04-08 | mAbProtein Co., Ltd. | Antibody that recognizes neoepitope of activated interleukin-18 proteins and application thereof |
| CN109870570A (zh) * | 2018-12-29 | 2019-06-11 | 广东云天抗体生物科技有限公司 | 一种检测猴il-18的酶联免疫试剂盒 |
| GB202007404D0 (en) * | 2020-05-19 | 2020-07-01 | Nasser Syed Muhammad Tahir | Treatment for viral respiratory infections |
| TW202210511A (zh) * | 2020-06-01 | 2022-03-16 | 美商阿法羅醫療股份有限公司 | 涉及il-18抗體之方法及治療 |
| CN112415191A (zh) * | 2020-11-06 | 2021-02-26 | 郑州人福博赛生物技术有限责任公司 | 一种白细胞三烯检测试剂盒 |
| EP4371573A4 (en) | 2021-07-13 | 2025-08-20 | National Univ Corporation Tokai National Higher Education And Research System | MEDICINAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE |
| WO2023067348A1 (en) | 2021-10-21 | 2023-04-27 | Biosirius Ltd | Treatment for virally-induced pneumonia |
| MX2024007616A (es) * | 2021-12-20 | 2024-09-04 | Avalo Therapeutics Inc | Métodos y tratamiento para la enfermedad de still de inicio en la edad adulta y la artritis idiopática juvenil de inicio sistemico que implica anticuerpos contra il-18. |
| PE20251671A1 (es) | 2022-03-15 | 2025-06-30 | Compugen Ltd | Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer |
| CN116236560A (zh) * | 2022-12-13 | 2023-06-09 | 华中科技大学同济医学院附属同济医院 | 人白细胞介素-37b在制备治疗鼻息肉的药品中的应用 |
| AU2024314970A1 (en) | 2023-06-20 | 2026-01-15 | Apollo Ap43 Limited | Anti-il-18 antibody therapy for treating atopic dermatitis |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US565332A (en) | 1896-08-04 | Toy for making soap-bubbles | ||
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4424200A (en) | 1979-05-14 | 1984-01-03 | Nuc Med Inc. | Method for radiolabeling proteins with technetium-99m |
| US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5185243A (en) | 1988-08-25 | 1993-02-09 | Syntex (U.S.A.) Inc. | Method for detection of specific nucleic acid sequences |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9206318D0 (en) | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| US5814468A (en) | 1996-03-27 | 1998-09-29 | Coulter International Corp. | Methods of enumerating receptor molecules for specific binding partners on formed bodies and in solution |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| CA2276216A1 (en) | 1998-06-24 | 1999-12-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | An artificial peptide capable of neutralizing the biological activity of interleukin-18 |
| DE69941267D1 (de) | 1998-12-10 | 2009-09-24 | Bristol Myers Squibb Co | Proteingerüste für antikörper-nachahmer und andere bindende proteine |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| AR022952A1 (es) | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL |
| TWI335336B (2) * | 2000-02-10 | 2011-01-01 | Abbott Gmbh & Co Kg | |
| ES2253358T3 (es) | 2000-03-31 | 2006-06-01 | Cambridge Antibody Technology Limited | Mejoras en la visualizacion del ribosoma. |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| CN1255392C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管生成抑制剂的秋水仙醇衍生物 |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| AU2004235595C1 (en) | 2003-04-30 | 2009-09-24 | Japan Science And Technology Agency | Human antihuman interleukin-18 antibody, fragment thereof and method of using the same |
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| US20050100965A1 (en) * | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| GB0500099D0 (en) | 2005-01-05 | 2005-02-09 | Cambridge Antibody Tech | Methods and means relating to protein variants |
| CN103555733A (zh) | 2005-01-05 | 2014-02-05 | F-星生物技术研究与开发有限公司 | 分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域 |
| BRPI0822099A2 (pt) * | 2007-12-21 | 2017-05-23 | Medimmune Ltd | membro de ligação isolado, uso de um membro de ligação isolado, método parav tratar um distúrbio, molécula de ácido nucléico isolada, célula hospedeira, e, método para produzir um membro de ligação |
| WO2009099545A1 (en) * | 2008-01-30 | 2009-08-13 | Abbott Laboratories | Compositions and methods for crystallizing antibody fragments |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2011
- 2011-12-20 KR KR1020137018576A patent/KR20140003467A/ko not_active Withdrawn
- 2011-12-20 CA CA2822515A patent/CA2822515C/en active Active
- 2011-12-20 MX MX2013007067A patent/MX2013007067A/es not_active Application Discontinuation
- 2011-12-20 CN CN2011800612426A patent/CN103339147A/zh active Pending
- 2011-12-20 EP EP11799104.2A patent/EP2655416A1/en not_active Withdrawn
- 2011-12-20 WO PCT/EP2011/073496 patent/WO2012085015A1/en not_active Ceased
- 2011-12-20 RU RU2013133846/10A patent/RU2013133846A/ru not_active Application Discontinuation
- 2011-12-20 US US13/993,537 patent/US9255144B2/en active Active
- 2011-12-20 AU AU2011347354A patent/AU2011347354A1/en not_active Abandoned
- 2011-12-20 JP JP2013545325A patent/JP2014508511A/ja active Pending
- 2011-12-20 BR BR112013015508-6A patent/BR112013015508B1/pt active IP Right Grant
-
2017
- 2017-03-06 AU AU2017201512A patent/AU2017201512A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2822515A1 (en) | 2012-06-28 |
| WO2012085015A9 (en) | 2013-06-27 |
| US9255144B2 (en) | 2016-02-09 |
| CN103339147A (zh) | 2013-10-02 |
| CA2822515C (en) | 2023-04-25 |
| MX2013007067A (es) | 2013-11-01 |
| AU2017201512A1 (en) | 2017-03-23 |
| JP2014508511A (ja) | 2014-04-10 |
| WO2012085015A1 (en) | 2012-06-28 |
| US20140004128A1 (en) | 2014-01-02 |
| AU2011347354A1 (en) | 2013-08-01 |
| BR112013015508B1 (pt) | 2022-04-05 |
| EP2655416A1 (en) | 2013-10-30 |
| BR112013015508A2 (pt) | 2016-10-11 |
| KR20140003467A (ko) | 2014-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013133846A (ru) | Антитела против il-18 и их применение | |
| JP2014508511A5 (2) | ||
| AU2019276486B2 (en) | Anti-interleukin-17A antibody, pharmaceutical composition thereof and use thereof | |
| JP2022177090A5 (2) | ||
| RU2015118180A (ru) | Антитела к бета-амилоиду | |
| CN110914304B (zh) | Cd96抗体、其抗原结合片段及医药用途 | |
| AU2010323037B2 (en) | Humanized anti-IL-10 antibodies for the treatment of systemic lupus erythematosus (SLE) | |
| RU2019113790A (ru) | Анти-lag-3 антитела и их композиции | |
| JP2021526022A5 (2) | ||
| JP2019534892A5 (2) | ||
| CN115461368A (zh) | 抗人白细胞介素-4受体α抗体及其制备方法和应用 | |
| JP2021501744A5 (2) | ||
| RU2009124591A (ru) | Соединения | |
| RU2010136940A (ru) | Антитела против альфа5-бета1 и их применение | |
| RU2018106364A (ru) | Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств | |
| CN111909273A (zh) | 人源化的抗-cxcr5抗体、其衍生物及它们的应用 | |
| JP2011526785A5 (2) | ||
| RU2015104760A (ru) | Связывающие kir3dl2 агенты | |
| JP2013543384A5 (2) | ||
| RU2008132968A (ru) | Антитела к рецептору тимусного стромального лимфопоэтина | |
| JP2011505810A5 (2) | ||
| US20220332811A1 (en) | Anti-interleukin-23 p19 antibodies and methods of use thereof | |
| RU2013105487A (ru) | Антитела против нейропилина и способы их применения | |
| EP2970461A1 (en) | Interferon alpha and omega antibody antagonists | |
| KR20250046324A (ko) | Il3를 표적화하는 항체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160926 |